MyLymphomaTeam

Triple-hit lymphoma (THL) is a rare and aggressive form of non-Hodgkin lymphoma, involving mutations in three genes: MYC, BCL2, and BCL6. Because of its aggressive nature, survival can be challenging, and overall survival time is generally less than two years. That said, research and treatment options are actively evolving Show Full Answer

Triple-hit lymphoma (THL) is a rare and aggressive form of non-Hodgkin lymphoma, involving mutations in three genes: MYC, BCL2, and BCL6. Because of its aggressive nature, survival can be challenging, and overall survival time is generally less than two years. That said, research and treatment options are actively evolving. Current and emerging treatment options that may improve outcomes include:

- Intensive chemotherapy combined with targeted therapies
- CNS prophylaxis — delivering chemotherapy directly to the central nervous system via IV or lumbar puncture, using drugs like methotrexate or cytarabine
- Bortezomib (Velcade) and ibrutinib (Imbruvica) — targeted drugs currently being evaluated in clinical trials for THL
- CAR T-cell therapy — an emerging approach where a person's own immune cells are engineered to attack cancer cells Because THL is so rare, it's difficult to study, and more research is needed to find more effective therapies. Speaking with an oncologist about clinical trials could open doors to newer treatments that may improve survival outcomes. Staying connected with others navigating THL on MyLymphomaTeam can also provide valuable real-world insights and support.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Triple-Hit Lymphoma: Your Guide